Genetically modified T cells to target glioblastoma
Despite advances in surgical procedures, radiation- and chemotherapy the outcome for patients with glioblastoma (GBM) remains poor. While GBM cells express antigens that are potentially recognized by T cells, GBMs prevent the induction of GBM-specific immune responses by creating an immunosuppressiv...
Main Authors: | Simone eKrebs, Tania G Rodríguez-Cruz, Christopher eDeRenzo, Stephen eGottschalk |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2013-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00322/full |
Similar Items
-
The debate about dendritic cells and macrophages in the kidney
by: Catherine eGottschalk, et al.
Published: (2015-09-01) -
The role of natural killer T cells in dendritic cell licensing, cross-priming and memory CD8+ T cell generation
by: Catherine eGottschalk, et al.
Published: (2015-07-01) -
Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme
by: Hany E. Marei, et al.
Published: (2021-08-01) -
Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors
by: Christopher DeRenzo, et al.
Published: (2019-02-01) -
Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme
by: Andrea eSchuessler, et al.
Published: (2014-10-01)